Skip to main content
. 2021 May 4;41(5):BSR20203362. doi: 10.1042/BSR20203362

Figure 7. The effects of Shensu IV on cell viability of puromycin-treated podocytes.

Figure 7

Compared with the control group, *P<0.05; compared with the puromycin group, #P<0.05.